Abnousi, Freddy <br/><br/>
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.  [electronic resource] 

 -  American heart journal  Jun 2017 
 - 147-155 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1097-6744 
<br/><br/><label>Standard No.: </label>10.1016/j.ahj.2017.02.031  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenosine Monophosphate--administration & dosage<br/>Administration, Oral<br/>Aged<br/>Cause of Death--trends<br/>Clopidogrel<br/>Coronary Angiography<br/>Coronary Artery Disease--diagnosis<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Female<br/>Follow-Up Studies<br/>Global Health<br/>Humans<br/>Incidence<br/>Infusions, Intravenous<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--epidemiology<br/>Percutaneous Coronary Intervention<br/>Postoperative Complications--epidemiology<br/>Purinergic P2Y Receptor Antagonists--administration & dosage<br/>Survival Rate--trends<br/>Ticlopidine--administration & dosage<br/>Time Factors